Eli Lilly Agrees to Acquire AtaiBeckley for $3.8 Billion

Eli Lilly and Company entered a definitive agreement on July 16, 2026, to acquire biopharmaceutical company AtaiBeckley for up to $3.8 billion in an all-cash deal. Lilly will pay $6.75 per share upfront, totaling approximately $2.8 billion in equity value. Shareholders may receive an additional $2.50 per share through Contingent Value Rights tied to regulatory milestones and the initiation of Phase 3 trials for AtaiBeckley's programs, VLS-01 and BPL-003.

The acquisition targets treatment-resistant depression and severe psychiatric disorders. AtaiBeckley's lead candidate, BPL-003, is an intranasal synthetic form of 5-MeO-DMT that has received breakthrough therapy designation from U.S. regulators and entered Phase 3 clinical trials. Following the announcement, AtaiBeckley's stock climbed to a four-year high of $7.22.

Lilly executives stated the move aims to help patients who have not responded to existing treatments. The deal is funded by the success of Lilly's GLP-1 drugs and aligns with a broader industry shift toward psychedelic therapeutics. The transaction is expected to close in the third quarter of 2026, pending approval from regulatory bodies and AtaiBeckley stockholders.